Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
An article by a group of Romanian researchers published in October this year may have some controversial implications — so we want to be very clear that we don’t think too much should be read into it unless their data can be replicated by others.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: antiandrogen, bicalutamide, effect, orientation, sexual | Leave a Comment »
A new report from Memorial Sloan-Kettering Cancer Center has documented patient outcomes at 10 years after high-dose, intensity-modulated radiation therapy (IMRT) for men initially diagnosed with clinically localized prostate cancer.
Filed under: Management, Treatment | Tagged: high-dose, IMRT, intensity-modulated radtiation therapy, localized, outcome | 2 Comments »
A Reuters report on a forthcoming study in the Journal of Clinical Oncology has suggested that some men with intermediate-risk prostate cancer may be able to safely defer treatment in favor of monitoring the disease over time (through active surveillance) for a period of at least 4 years.
Filed under: Living with Prostate Cancer, Management | Tagged: active surveillance, intermediate risk, outcome | 6 Comments »
The Australian Research Centre in Sex, Health and Society at La Trobe University, Melbourne, Australia is conducting an international survey of men’s experiences of sexual activity following treatment for prostate cancer.
Filed under: Living with Prostate Cancer | Tagged: sexual activity, sexuality, survey, Treatment | 10 Comments »
There is an interesting article in the November issue of the European Journal of Cancer that addresses the quality of consumer information available through the Internet about the value of PSA-based testing for prostate cancer.
Filed under: Diagnosis, Risk | Tagged: consumer, education, Internet, PSA, screening, testing | 12 Comments »
According to a media release this morning from Genomic Health, Inc., initial data from a large study has identified 295 genes that are strongly associated with clinical recurrence following radical prostatectomy.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: genes, localized, progression, recurrence, test | 1 Comment »
Overall life expectancy of men in the US continues to rise. As a consequence, the way we treated localized prostate cancer in men of ≥ 70 years of age in 1990 will probably not be relevant or appropriate to the way we need to treat such men in 2020 (or perhaps even today).
Filed under: Uncategorized | Tagged: age, elderly, high, localized, risk, Treatment | 2 Comments »
A re-analysis of data from the Antwerp (Belgium) section of the European Randomized Study of Screening for Prostate Cancer (ERSPC) has offered us some further insight into the frequency of PSA testing necessary to identify less and more aggressive forms of prostate cancer.
Filed under: Diagnosis, Risk | Tagged: aggressive, interval, PSA, risk, screening, test | 5 Comments »
Following the recent decision in the UK not to implement a broad, national, PSA-based, prostate cancer screening initiative (on which we have previously commented), many readers will be interested in the reactions and thoughts of John Neate, the executive director of the UK’s Prostate Cancer Charity, which appear in today’s issue of The Guardian newspaper.
Filed under: Diagnosis, Risk | Tagged: education, patient, physician, screening, testing UK | 1 Comment »
A new study by a French research team has suggested that there may be a prognostic relationship between the pretreatment testosterone (T) level and the post-surgical pathology of men who undergo radical prostatectomy (RP) for treatment of localized prostate cancer.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: pathology, radical prostatectomy, T, testosterone | 2 Comments »
A new article just published on-line in the Journal of Clinical Oncology is entitled “Impact of age at diagnosis on prostate cancer treatment and survival.”
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: age, outcome, risk, Treatment | Leave a Comment »
Data from a small Phase II trial of cilengitide suggest that it has minimal clinical effect in the treatment of men with non-metastatic, castration-resistant prostate cancer (CRPC). They also suggest that levels of circulating T-cells (CTCs) are of limited utility in monitoring the progression of this patient group.
Filed under: Drugs in development | Tagged: castration-resistant, cilengitide, circulating T-cell, CRPC, CTC | Leave a Comment »
According to a new report in The Lancet, just published on line, a daily aspirin regimen reduces deaths due to several common cancers — including those caused by prostate cancer.
Filed under: Diagnosis, Prevention, Risk | Tagged: aspirin, mortality, risk | Leave a Comment »
Although there is no information (as yet) on the web site of the UK’s National Screening Committee (NSC), a BBC News report has stated that the NSC has “recommended against a screening programme for prostate cancer, saying its potential harms would outweigh any benefits.”
Filed under: Diagnosis, Risk | Tagged: PSA, risk, screening, testing, UK | 4 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site